gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FATEHealthcareBiotechnology

Fate Therapeutics, Inc. (FATE)

$2.09+2.45%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.09▲ 75.63% in range
Nov 4, 2025Low $0.96 · High $3.11Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Fate Therapeutics closed at $2.09 on Nov 4, up 2.45%, 32.8% below its 52-week closing high. Volume of 724.0K shares was 0.63× its 20-day average (below normal).

Split-adjusted performance: -8.7% over one month, -8.7% over six months, +65.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $2.08M, up 9.2% from a year earlier, with a net margin of -1448.6%.

Short interest was 10.6M shares at the Oct 15 settlement, down 1.3% from the prior report (10.4% of float, 8.7 days to cover).

Market cap$250.4M119.8M shares
Revenue · quarter$2.1M+9.2% YoY
Diluted EPS$-0.25—
P/E · TTM—P/S 38.6×
Net margin-1,448.6%Gross 100.0%
Dividend yieldNone
52-week range0.96 – 3.11−32.8% from high
Volume724.0K0.63× 20-day avg
Volatility · 60d56.4%Annualised
Short % of float10.4%8.7 days to cover
Net cash$153.8MCash $153.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.7%1M −8.7%3M −16.1%6M −8.7%YTD +112.7%1Y +65.9%3Y +20.8%5Y −96.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum60
Revenue growth52
Net margin29
Value (low P/E)—
Size49

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short10.6M−1.3% vs prior
Days to cover8.7Settled Oct 15
% of float10.4%
Short vol. 10d52.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FATEFate Therapeutics$2.09+2.45%−8.7%+9.2%−1448.6%—$250.4M
ALECAlector$2.28+11.22%−11.3%−57.8%−692.5%—$254.6MCompare
CABACabaletta Bio$1.420.00%−61.9%———$240.8MCompare
LCTXLineage Cell Therapeutics$1.03+1.98%−28.0%−61.3%138.6%—$260.5MCompare
LXEOLexeo Therapeutics$3.23+3.86%−48.2%———$265.1MCompare
PROKProKidney$1.12+4.67%−42.9%−32.1%−18948.0%—$234.1MCompare
DTILPrecision BioSciences$8.12+16.50%+8.0%−100.0%——$224.1MCompare
IKTInhibikase Therapeutics$1.57+5.74%−22.1%———$218.4MCompare
PALIPalisade Bio$1.25+1.63%−37.5%—−2114.8%—$217.8MCompare

News about Fate Therapeutics

All news →
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell TherapiesGlobeNewswire Inc. · Oct 12, 2026▲ PositiveFate Therapeutics to Participate in Upcoming Fourth Quarter 2026 ConferencesGlobeNewswire Inc. · Oct 1, 2026NeutralFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026GlobeNewswire Inc. · Sep 16, 2026▲ Positive

Quick answers

What does Fate Therapeutics do?
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders.
What is FATE's market cap?
$250.42M, based on the Nov 4 close of $2.09.
Does Fate Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FATE is sold short?
10.6M shares, 10.4% of float, as of Oct 15, 2026.
What sector is FATE in?
Healthcare, in the Biotechnology industry.

About Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

HQ: San Diego, CA161 employeesListed Oct 1, 2013fatetherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology